In Observance of U.S. Holiday, Martin Luther King Jr. Day, Agilent Cross Lab/ iLab Operations Software will be closed during U.S. hours on Monday January 21st, 2019. We will resume regular U.S. support hours on Tuesday January 22nd, 2018. EU and APAC Support will remain open during this time. For urgent matters, please add "Urgent" to the ticket/ email subject or press "1", when prompted, to escalate a call on the iLab Support phone and we will prioritize those requests first.

Center for Cancer Genome Discovery

Getting Started

You must have an iLab account to request a project from the CCGD.


To register with iLab:

  1) Click HERE to generate an iLab account.  All fields are required. 

  2) Once you have submitted your account request, you will receive a password from iLab support within 1 business day of your submittal.

  3) With you iLab password, click HERE to log into iLab.  Or log in at the top right corner.

  4) To find all cores using iLab at DFCI, click the "list all cores" link on the left panel.

Overview of the Mission

The mission of CCGD is to develop new technologies for the analysis of cancer genomes and to provide access to these technologies to basic, translational and clinical investigators. In this latter role, CCGD participates in the design, execution and analysis of both single gene and whole genome focused projects.

More specifically, we focus on the discovery of genomic alterations in human cancer and evaluate the clinical significance of these alterations for cancer diagnosis and therapy. Our expertise lies in genome-wide detection of a myriad of genomic aberrations, including single base pair mutations, small insertions and deletions, chromosomal rearrangements and copy number changes. In addition, in collaboration with the Center for Functional Cancer Epigenetics (CFCE) we study the epigenome by sequencing DNA with altered methylation status, chromatin remodeling or histone modifications. The technologies that have been developed for these purposes are Sequenom iPLEX/hME Mass Spectrometry-based detection of DNA mutations in a complex background and the HiSeq massively-parallel sequencing system from Illumina.


Learn more about the Center for Cancer Genome Discovery.


Matthew Meyerson, MD, PhD | Director

Information for Users External to DFCI

Purchase Orders are to be made out to:

Dana Farber Cancer Institute

General Accounting, BP-425

450 Brookline Avenue

Boston, MA 02215-5450


Note to Partners, Harvard, Boston Children’s and Tufts researchers:

  • Partners Health Care (includes MGH, BWH, McLean, Spaulding, etc): choose vendor 0000008573
  • Harvard (includes HMS,Dental, Wyss, HSPH, etc.): choose vendor site: 01_PRIMARY
  • Tufts University: choose Supplier 0000000655
  • Boston Children’s Hospital: choose vendor 0000001886


 If you are using a PO from an institution other than one under which you signed in, you must stop and contact the DFCI iLab staff at


Name Role Phone Email Location
Aaron Thorner, PhD
Associate Director

Anwesha Nag, PhD
Group Leader